Evidence map›Paper›PMID 27756323›Full record

ArticleJournal of translational medicine2016

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.

Ana I Robles, Karina Standahl Olsen, Dana W T Tsui, Vassilis Georgoulias, Jenette Creaney, Katalin Dobra, Mogens Vyberg, Nagahiro Minato, Robert A Anders, Anne-Lise Børresen-Dale and 8 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ana I RoblesLaboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, USA.
Karina Standahl OlsenDepartment of Community Medicine, UiT The Artic University of Norway, Tromsø, Norway.
Dana W T TsuiDepartment of Pathology and Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Vassilis GeorgouliasDepartment of Medical Oncology, School of MedicineUniversity of Crete, Heraklion, Greece.
Jenette CreaneyNational Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia.
Katalin DobraDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Mogens VybergDepartment of Clinical Medicine, Institute of Pathology, Aalborg University Hospital, Aalborg University, Aalborg, Denmark.
Nagahiro MinatoDepartment of Immunology and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Robert A AndersDepartment of Pathology, Johns Hopkins University, Baltimore, USA.
Anne-Lise Børresen-DaleDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Jianwei ZhouDepartment of Molecular Cell Biology & Toxicology, Cancer Center School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.
Pål SætromDepartment of Computer and Information Science, NTNU, Trondheim, Norway.
Boye Schnack NielsenMolecular Histology Bioneer A/S, Hørsholm, Denmark.
Michaela B KirschnerDivision of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Hans E KrokanDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Vassiliki PapadimitrakopoulouDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson, Houston, USA.
Ioannis TsamardinosDepartment of Computer Science, University of Crete, Heraklion, Greece.
Oluf D RøeDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. oluf.roe@ntnu.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of biomarker research is to identify clinically valid markers. Despite decades of research there has been disappointingly few molecules or techniques that are in use today. The "1st International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation", was held June 16th and 17th 2016, at the Knowledge Center of the St. Olavs Hospital in Trondheim, Norway, under the auspices of the Norwegian University of Science and Technology (NTNU) and the HUNT biobank and research center. The Symposium attracted approximately 100 attendees and invited speakers from 12 countries and 4 continents. In this Symposium original research and overviews on diagnostic, predictive and prognostic cancer biomarkers in serum, plasma, urine, pleural fluid and tumor, circulating tumor cells and bioinformatics as well as how to implement biomarkers in clinical trials were presented. Senior researchers and young investigators presented, reviewed and vividly discussed important new developments in the field of clinical biomarkers of cancer, with the goal of accelerating biomarker research and implementation. The excerpts of this symposium aim to give a cutting-edge overview and insight on some highly important aspects of clinical cancer biomarkers to-date to connect molecular innovation with clinical implementation to eventually improve patient care.

Indexed as

InternationalityBiomarkers, TumorDatabases as TopicHumansNeoplasmsNorwayReproducibility of ResultsBiomarkers, TumorBioinformaticsCirculating biomarkersCirculating tumor cellsDNA repairEarly detectionEarly diagnosis

Identifiers

PMID27756323
PMCPMC5069785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.